- Tetra Bio-Pharma and Targeted Pharmaceuticals enter into an agreement to further its collaboration and co-development activities to advance Antiviral Central Nervous System Program
- The addressable global market for central nervous system drugs is expected to grow to $163.05 billion in 2025
OTTAWA, ON / March 26, 2021 / Tetra Bio-Pharma Inc. (“Tetra” or the “Company”)(TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development announce they have initiated other research projects with Targeted Pharmaceuticals through its research agreement with the George Mason University NCBID to investigate the potential benefits of ARDS-003 in neuroinflammation and other antiviral applications.
The global central nervous system drugs market is expected to grow from $125.28 billion in 2020 to $163.05 billion in 2025 at a CAGR of 6%. (ref: Feb 2021, The Business research company).
Dr. Guy Chamberland, CEO and CRO commented, “We have initiated this new research agreement to further understand the potential therapeutic benefits of ARDS-003 in treating inflammatory conditions of the brain as well as learning more about the potential use of the drug candidate in other antiviral applications. The partnership with Targeted provides expertise into these areas of drug development that are critical for expanding the potential Return on Investment of our lead drug candidate ARDS-003.”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) is a biopharmaceutical pioneer in immunomodulator drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Our evidence-based scientific approach has enabled us to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
About Targeted Pharmaceuticals LLC
Targeted Pharmaceuticals is a clinical-stage pharmaceutical company focused on treatments for oncology and central nervous system disorders.
Learn more at https://www.targetedpharma.com
About George Mason University
George Mason University is Virginia’s largest public research university. Located near Washington, D.C., Mason enrolls more than 37,000 students from 130 countries and all 50 states. The National Center for Biodefense and Infectious Diseases (NCBID) at Mason focuses on host-pathogen interactions using proteomics and nanotechnology as they are applied to diagnostic, therapeutic, and vaccine development. NCBID manages The Biomedical Research Lab (BRL), one of thirteen Regional Biocontainment Laboratories in the U.S. constructed with funding support from the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), performing pioneering research of infectious diseases, both emerging and potential bio threat agents.
Learn more at www.ncbid.gmu.edu
The College of Science at Mason is a leader in scientific discovery creating innovative solutions for the rapidly changing needs of today’s world. Mason’s College of Science blends traditional science education with sought-after programs in disciplines as diverse as personalized medicine, infectious diseases, geoinformatics, climate dynamics, materials science, astronomy, forensic science, and applied mathematics. The College encourages meaningful education and research at all levels offering innovative undergraduate programs, minors, certificates, and graduate degree opportunities, as well as global, transfer-focused, and online, or hybrid, programs that allow professionals the opportunity to reskill or change careers.
Learn more at www.science.gmu.edu
Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.